Clinical Trial Update: A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study [Phase 2]

View source ↗

Summary

Pfizer's Phase 2 extension study for hypertrophic scars from prior breast scar revision surgery (enrolling subjects from B5301001) was terminated; results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery

Drugs mentioned

• Pfizer product from B5301001 extension study

Snippet

Sponsor: Pfizer | Conditions: Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery | Phase 2 | Status: TERMINATED | Results posted: 2016-01-28